Results 121 to 130 of about 12,145 (180)
Some of the next articles are maybe not open access.
SSRN Electronic Journal, 2014
This case is an updated version of “Netflix Inc.: DVD Wars” (UVA-M-0763), and was written as a replacement for it.A financial analyst is asked to appraise the value of Netflix’s stock at a time of unprecedented turmoil for the company. This case introduces customer lifetime value (CLV) as a useful metric for subscription-based businesses.
Jeremy Chapman Hutchison-Krupat +2 more
openaire +1 more source
This case is an updated version of “Netflix Inc.: DVD Wars” (UVA-M-0763), and was written as a replacement for it.A financial analyst is asked to appraise the value of Netflix’s stock at a time of unprecedented turmoil for the company. This case introduces customer lifetime value (CLV) as a useful metric for subscription-based businesses.
Jeremy Chapman Hutchison-Krupat +2 more
openaire +1 more source
SSRN Electronic Journal, 2017
The case can be taught in an introductory corporate finance course or to more experienced students or executives to spur a discussion about share repurchases and corporate financial strategies in general. If used in an introductory course, the case is most effective if preceded by a traditional dividend class. It follows a portfolio manager of Johnson &
Kenneth M. Eades, Justin Brenner
openaire +1 more source
The case can be taught in an introductory corporate finance course or to more experienced students or executives to spur a discussion about share repurchases and corporate financial strategies in general. If used in an introductory course, the case is most effective if preceded by a traditional dividend class. It follows a portfolio manager of Johnson &
Kenneth M. Eades, Justin Brenner
openaire +1 more source
Regenerative Medicine, 2006
Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at two US sites for its lead product, Anginera, a cell-based epicardial patch therapy.
openaire +2 more sources
Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at two US sites for its lead product, Anginera, a cell-based epicardial patch therapy.
openaire +2 more sources
SSRN Electronic Journal, 2006
Hydrochem, Inc. produces only one product — condutronic plates. The company uses an actual process costing system but is considering changing to a standard costing system. Manufacturing costs consist of raw material, direct labor and manufacturing overhead and the company uses full absorption costing.
openaire +1 more source
Hydrochem, Inc. produces only one product — condutronic plates. The company uses an actual process costing system but is considering changing to a standard costing system. Manufacturing costs consist of raw material, direct labor and manufacturing overhead and the company uses full absorption costing.
openaire +1 more source
Pharmacogenomics, 2002
Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care. Toward this end, the company analyzes genetic variations in both normal and tumor cells, including SNPs, haplotypes, loss of heterozygosity, and gene expression levels.
Ann E, Ferentz, Joseph S, Mohr
openaire +2 more sources
Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care. Toward this end, the company analyzes genetic variations in both normal and tumor cells, including SNPs, haplotypes, loss of heterozygosity, and gene expression levels.
Ann E, Ferentz, Joseph S, Mohr
openaire +2 more sources
SSRN Electronic Journal, 2006
The MinderSoft case explores the entrepreneur's attempt to raise a first round of venture capital. The founder and venture fund's valuation differ by a large amount. The founder must decide whether to accept this offer or search further. The case is designed to help students compare frequently used valuation frameworks including the venture capital ...
Susan Chaplinsky, Richard D. Crawford
openaire +1 more source
The MinderSoft case explores the entrepreneur's attempt to raise a first round of venture capital. The founder and venture fund's valuation differ by a large amount. The founder must decide whether to accept this offer or search further. The case is designed to help students compare frequently used valuation frameworks including the venture capital ...
Susan Chaplinsky, Richard D. Crawford
openaire +1 more source
Darden Business Publishing Cases, 2006
In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug.
Robert F. Bruner, Sean Carr
openaire +1 more source
In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug.
Robert F. Bruner, Sean Carr
openaire +1 more source
Darden Business Publishing Cases, 2009
This case is designed as an introductory exercise to familiarize students with several methods used to value early-stage companies. The value of a young biotech company is compared under the venture capital (VC), discounted cash flow (DCF), and real option methods of valuation.
openaire +1 more source
This case is designed as an introductory exercise to familiarize students with several methods used to value early-stage companies. The value of a young biotech company is compared under the venture capital (VC), discounted cash flow (DCF), and real option methods of valuation.
openaire +1 more source
Pharmacogenomics, 2008
Sequenom is an established genomic analysis company with two principal divisions: genetic analysis systems and reagents, and noninvasive prenatal diagnostics. As an industry innovator in DNA detection technology, Sequenom's benchtop MassARRAY Compact system allows a direct mass measurement of nucleic acids, providing unparalleled precision and ...
Amy, Cullinan, Charles, Cantor
openaire +2 more sources
Sequenom is an established genomic analysis company with two principal divisions: genetic analysis systems and reagents, and noninvasive prenatal diagnostics. As an industry innovator in DNA detection technology, Sequenom's benchtop MassARRAY Compact system allows a direct mass measurement of nucleic acids, providing unparalleled precision and ...
Amy, Cullinan, Charles, Cantor
openaire +2 more sources
SSRN Electronic Journal, 2008
A regional director of a consulting firm must decide how to compete for a major consulting contract. Appshop can take a level payment contract, a lower level payment with a prospective bonus given high performance, or bid on an RFP where a significant reward is given contingent on the client's savings.
Samuel E. Bodily, Eric Clark
openaire +1 more source
A regional director of a consulting firm must decide how to compete for a major consulting contract. Appshop can take a level payment contract, a lower level payment with a prospective bonus given high performance, or bid on an RFP where a significant reward is given contingent on the client's savings.
Samuel E. Bodily, Eric Clark
openaire +1 more source